The DEA officially opens historic marijuana rescheduling hearings as testimony begins in the effort to move cannabis to Schedule III
The federal government’s long-awaited cannabis moment has started and is what happened on day one of the marijuana rescheduling hearing. While many industry observers hoped for dramatic testimony or an immediate indication of where the Drug Enforcement Administration (DEA) might ultimately rule, the opening day was largely devoted to procedural matters shaping the hearings over the next several weeks.
The administrative hearing, taking place at DEA headquarters in Arlington, Virginia, is scheduled to run from June 29 through July 15. It is designed to collect factual evidence and expert testimony on whether marijuana should be transferred from Schedule I to Schedule III under the federal Controlled Substances Act. The proceedings are open to the public in limited capacity, and the DEA has said an official transcript will be published after the hearings conclude.
RELATED: Medical Marijuana May Help With Brain Cancer
Unlike a courtroom trial, the hearing is an administrative proceeding overseen by a DEA administrative law judge. Participants include government representatives, medical experts, researchers, industry organizations, attorneys, and other stakeholders selected by the agency. Their role is to present evidence regarding marijuana’s medical use, abuse potential, scientific research, and the broader implications of changing its federal classification.
The first day focused primarily on establishing the framework for the hearing. The administrative law judge reviewed procedures, clarified how testimony and evidence would be presented, addressed scheduling issues, and outlined expectations for participants. While advocates on both sides have spent months preparing extensive testimony, the opening session served mainly to organize what is expected to be two weeks of detailed presentations.
The hearing represents a fresh start after an earlier rescheduling process stalled in early 2025 amid legal challenges and procedural disputes. The earlier effort was postponed before testimony could be completed. Following new action by the Department of Justice this spring, the previous proceeding was withdrawn and replaced with the expedited hearing now underway.
What makes this hearing particularly important is its potential impact on the future of federal cannabis policy. Moving marijuana to Schedule III would not legalize cannabis nationally, but it could significantly reduce research barriers and eliminate the federal tax penalties imposed under Internal Revenue Code Section 280E for many cannabis businesses. It would also represent the federal government’s most significant acknowledgment to date marijuana has accepted medical uses.
Industry leaders will be watching closely as testimony unfolds over the coming days. Witnesses are expected to discuss scientific evidence, medical applications, public health, criminal justice, economics, and the experiences of states who have legalized medical or adult-use cannabis. Supporters argue the current Schedule I classification no longer reflects scientific evidence or the reality when dozens of states now regulate legal cannabis markets. Opponents are expected to emphasize largely debunked concerns about safety, youth access, addiction, and public health.
RELATED: Texan Ken Paxton Doubles Down on Cannabis Opposition
Although the opening day did not produce major fireworks, it officially launched what could become one of the most consequential federal cannabis proceedings in modern history. By establishing the hearing process and moving testimony forward on schedule, the DEA has taken another step toward resolving a question which has shaped American marijuana policy for more than 50 years.
The real substance of the hearing now lies ahead. As expert witnesses begin presenting evidence over the coming days, policymakers, cannabis businesses, investors, healthcare professionals, and millions of Americans will be watching closely to see whether federal marijuana policy is finally poised for historic change.
